

ABCD nationwide exenatide QW audit – follow up visit data collection form



Date / / (dd/mm/yyyy) Name of Clinician

NHS Number
 Forename
 Surname
 Date of Birth / / (dd/mm/yyyy)
 Gender Male Female

Has this patient had bariatric surgery? No Yes Date / / (dd/mm/yyyy)
 Patient still taking QW?
 Yes Temporarily Stopped Permanently Stopped Date / / (dd/mm/yyyy)
 Reason stopped: (Tick all below that apply)
 Efficacy Patient Choice GI Side Effect Other:

AFFIX PATIENT LABEL HERE

Who Administers exenatide QW?
 Patient Relative Practice Nurse Community (District) Nurse Uncertain Other:

Dyspepsia Flatulence Bloating Constipation
 Diarrhoea Vomiting Nausea

Test Results

Blood Pressure SBP mmHg Date of test / / (dd/mm/yyyy) Current Weight kg Date of test / / (dd/mm/yyyy)
 DBP mmHg

HbA1c Percentage % or mmol/mol mmol/mol Date of test / / (dd/mm/yyyy)
 Lipids Triglyceride Value mmol/L Date of test / / (dd/mm/yyyy)
 HDL Value mmol/L
 Total Cholesterol mmol/L

Alanine Aminotransferase - ALT IU/L Date of measure / / (dd/mm/yyyy) Serum Creatinine mmol/L Date of measure / / (dd/mm/yyyy)

Side Effects

Information about adverse event reporting can be found at <http://www.yellowcard.gov.uk>. Adverse events should also be reported to BMS Medical Information at the following email address: medical.information@bms.com.

GI side effects ascribed to exenatide QW since last visit No Yes, but transient Yes, continuing
 If Yes, Please tick all that apply: Dyspepsia Flatulence Bloating Constipation Diarrhoea Vomiting Nausea

Are there new skin nodules at the site of administration? No Yes Uncertain

Other possible side effects Please specify (including pancreatitis, pancreatic cancer, thyroid cancer)

Was there hypoglycaemia No Yes Uncertain Number of events since last visit (best estimate)

Minor Hypoglycaemia - Blood glucose <3.3 mmol/L, symptoms consistent with hypoglycaemia, transient, did not require special treatment, did not interfere with daily activities

Moderate hypoglycaemia - Blood glucose <3.3 mmol/L, symptoms consistent with hypoglycaemia, causing low level of inconvenience or possibly interfering with daily activities, easily treated.

Severe hypoglycaemia - required assistance of another person to treat hypoglycaemia (defined as patient could not have self treated – exclude cases where patient could have self-treated but a kind person helped).

Record current medication, before any changes made at this visit

Metformin	<input type="text"/> Metformin	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
Sulphonylurea	<input type="text"/> Glimpiride <input type="text"/> Glipizide <input type="text"/> Chlorpropamide <input type="text"/> Gliclazide	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
	<input type="text"/> Gliclazide MR <input type="text"/> Gliclazide SR <input type="text"/> Tolbutamide <input type="text"/> Glibenclamide		
Pioglitazone	<input type="text"/> Pioglitazone	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
Meglitinides	<input type="text"/> Nateglinide <input type="text"/> Repaglinide	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
Alpha-glucosidase inhibitors	<input type="text"/> Acarbose	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
GLP-1 receptor agonists	<input type="text"/> Exenatide (Micrograms per day) <input type="text"/> Liraglutide (Milligrams per day)	Total dose including any in combined preparations	Total Dose <input type="text"/> mcg/mg/Day
	<input type="text"/> Lixisenatide (Micrograms per day)		
DPP4 inhibitors	<input type="text"/> Sitagliptin <input type="text"/> Vildagliptin <input type="text"/> Saxagliptin <input type="text"/> Linagliptin <input type="text"/> Alogliptin	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
SGLT2 inhibitors	<input type="text"/> Dapagliflozin <input type="text"/> Canagliflozin <input type="text"/> Empagliflozin	Total dose including any in combined preparations	Total Dose <input type="text"/> mg/Day
Insulin - Rapid / Short Acting	<input type="text"/> Insulin Lispro <input type="text"/> Insulin Aspart <input type="text"/> Insulin Glulisine	Total dose including any in combined preparations	Total Dose <input type="text"/> IU/Day
	<input type="text"/> Highly purified Animal <input type="text"/> Insulin Human Sequence <input type="text"/> Other/Unsure		
Insulin - Long / Intermediate Acting	<input type="text"/> Insulin Detemir <input type="text"/> Insulin Glargine <input type="text"/> Insulin zinc Suspension	Total dose including any in combined preparations	Total Dose <input type="text"/> IU/Day
	<input type="text"/> Protamine zinc insulin <input type="text"/> Isophane - Highly purified Animal		
	<input type="text"/> Isophane - Insulin Human Sequence <input type="text"/> Insulin Degludec <input type="text"/> Other/Unsure		
Insulin - Biphasic	<input type="text"/> Biphasic Insulin Lispro <input type="text"/> Biphasic Insulin Aspart	Total dose including any in combined preparations	Total Dose <input type="text"/> IU/Day
	<input type="text"/> Biphasic Isophane Insulin – Human		
	<input type="text"/> Biphasic Isophane Insulin – Animal <input type="text"/> Other/Unsure		

Other antidiabetic medications Or medications which could affect glycaemic control

Anit-obesity medication Orlistat (Xenical) Total Dose mg/Day

Patient opinion of antidiabetic treatment 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6

Any other patient comments? Any other doctor/nurse comments?

010414MVF4412